Division of Human Nutrition, Wageningen University and Research Center, PO Box 8129, 6700, EV, Wageningen, The Netherlands.
BMC Med Genet. 2012 May 18;13:39. doi: 10.1186/1471-2350-13-39.
Genetic variations in TGFB1 gene have been studied in relation to coronary heart disease (CHD) risk, but the results were inconsistent.
We performed a systematic review of published studies on the potential role of TGFB1 genetic variation in CHD risk. Articles that reported the association of TGFB1 genetic variants with CHD as primary outcome were searched via Medline and HuGE Navigator through July 2011. The reference lists from included articles were also reviewed.
Data were available from 4 studies involving 1777 cases and 7172 controls for rs1800468, 7 studies involving 5935 cases and 10677 controls for rs1800469, 7 studies involving 6634 cases and 9620 controls for rs1982073, 5 studies involving 5452 cases and 9999 controls for rs1800471, and 4 studies involving 5143 cases and 4229 controls for rs1800472. The pooled odds ratios (ORs) for CHD among minor T allele carriers of rs1800469, minor C allele carriers of rs1982073, and minor C allele carriers of rs1800471 versus homozygous major allele carriers was 1.14 (95% confidence interval [CI]: 1.05-1.24), 1.18 (95% CI: 1.04-1.35), and 1.16 (95% CI: 1.02-1.32), respectively. No substantial heterogeneity for ORs was detected among the included Caucasian populations for all SNPs. However, for rs1800471, the statistical significance disappeared after adjusting for potential publication bias. No significant association was found between rs1800468 and rs1800472 variants and CHD risk.
Minor allele carriers of two genetic variants (rs1800469 and rs1982073) in TGFB1 have a 15% increased risk of CHD.
已有研究探讨了转化生长因子β1(TGFB1)基因的遗传变异与冠心病(CHD)风险的关系,但结果并不一致。
我们对 TGFB1 遗传变异与 CHD 风险关系的相关研究进行了系统综述。通过 Medline 和 HuGE Navigator 检索了截至 2011 年 7 月发表的关于 TGFB1 遗传变异与 CHD 关系的研究,纳入了以 TGFB1 遗传变异为主要结局指标的研究。同时还对纳入文献的参考文献进行了综述。
共有 4 项研究(纳入 1777 例病例和 7172 例对照)针对 rs1800468、7 项研究(纳入 5935 例病例和 10677 例对照)针对 rs1800469、7 项研究(纳入 6634 例病例和 9620 例对照)针对 rs1982073、5 项研究(纳入 5452 例病例和 9999 例对照)针对 rs1800471、4 项研究(纳入 5143 例病例和 4229 例对照)针对 rs1800472 进行了报道。与 TGFB1 基因 rs1800469 次要 T 等位基因携带者、rs1982073 次要 C 等位基因携带者和 rs1800471 次要 C 等位基因携带者相比,杂合子主要等位基因携带者的 CHD 比值比(OR)分别为 1.14(95%置信区间 [CI]:1.05-1.24)、1.18(95% CI:1.04-1.35)和 1.16(95% CI:1.02-1.32)。在所有纳入的高加索人群中,各 SNP 间的 OR 均无明显异质性。然而,对于 rs1800471,在调整潜在的发表偏倚后,其统计学意义消失。rs1800468 和 rs1800472 变异与 CHD 风险无显著相关性。
TGFB1 基因的两个遗传变异(rs1800469 和 rs1982073)的次要等位基因携带者患 CHD 的风险增加 15%。